Escherichia coli: development of carbapenem resistance during therapy.

Tao Hong, Ellen Smith Moland, Baha Abdalhamid, Nancy D. Hanson, Jie Wang, Cindy Sloan, Diane Fabian, Awny Farajallah, Jerome Levine, Kenneth S. Thomson

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

Original languageEnglish (US)
Pages (from-to)e84-86
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume40
Issue number10
DOIs
StatePublished - May 15 2005

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Escherichia coli: development of carbapenem resistance during therapy.'. Together they form a unique fingerprint.

  • Cite this

    Hong, T., Moland, E. S., Abdalhamid, B., Hanson, N. D., Wang, J., Sloan, C., Fabian, D., Farajallah, A., Levine, J., & Thomson, K. S. (2005). Escherichia coli: development of carbapenem resistance during therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 40(10), e84-86. https://doi.org/10.1086/429822